Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Galapagos, Servier deal

    Galapagos N.V. (Euronext:GLPG;Pink:GLPYY), Mechelen, Belgium Servier, Neuilly-sur-Seine, France Business: Autoimmune Galapagos received an undisclosed second partial milestone payment from Servier under a July 2010 deal…

    Published on 9/1/2014
  • Gamida Cell, Novartis deal

    Gamida Cell Ltd., Jerusalem, Israel Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer, Gene/Cell therapy Gamida Cell granted Novartis an option to acquire Gamida Cell and a 15% equity stake in the …

    Published on 9/1/2014
  • Genentech, Incyte, Roche deal

    Genentech Inc., South San Francisco, Calif. Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Roches Genentech Inc. unit partnered with Incyte on a non-…

    Published on 9/1/2014
  • GlaxoSmithKline, Pernix Therapeutics deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), Morristown, N.J. Business: Neurology Pernix said the closing of a deal granting GlaxoSmithKline U.S. rights to …

    Published on 9/1/2014
  • Hanmi Pharmaceutical, Luye deal

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Luye Pharma Group Ltd. (HKSE:2186), Shanghai, China Business: Cancer Hanmi granted Luye Pharma exclusive rights to develop and commercialize poziotinib (…

    Published on 9/1/2014
  • Idenix, Merck deal

    Idenix Pharmaceuticals Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck completed its tender offer to acquire Idenix for $24.50 per share in cash, or about $3.9 …

    Published on 9/1/2014
  • Illumina, AstraZeneca, Sanofi, J&J deal

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Diagnostic, …

    Published on 9/1/2014
  • Intellikine, Infinity deal

    Intellikine Inc., La Jolla, Calif. Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. Business: Cancer Infinity paid $5 million to Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), which acquired …

    Published on 9/1/2014
  • InterMune, Roche deal

    InterMune Inc. (NASDAQ:ITMN), Brisbane, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pulmonary Roche began its tender offer to acquire InterMune for $74 per share, or about $8.3 billion in cash. The …

    Published on 9/1/2014
  • Jazz Pharmaceuticals, Sigma-Tau deal

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Sigma-Tau Group, Pomezia, Italy Business: Hepatic Jazz completed a deal reacquiring from Sigma-Tau rights in the Americas to defibrotide for $75 million up front. …

    Published on 9/1/2014
  • Kadimastem, Merck deal

    Kadimastem Ltd. (Tel Aviv:KDST), Ness Ziona, Israel Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Autoimmune Kadimastem and Mercks Merck Serono S.A. division expanded a 2012 deal to use Kadimastems …

    Published on 9/1/2014
  • KaloBios, Sanofi deal

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO), South San Francisco, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Infectious The companies terminated a 2010 deal and KaloBios regained all rights to KB001-…

    Published on 9/1/2014
  • Kyowa Hakko Kirin, Japan Blood Products Organization deal

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Japan Blood Products Organization, Tokyo, Japan Business: Hematology Kyowa granted Japan Blood Products Organization rights to market KW-3357 in Japan. Kyowa will …

    Published on 9/1/2014
  • MabVax, Telik deal

    MabVax Therapeutics Inc., San Diego, Calif. Telik Inc. (OTCQB:TELK), Palo Alto, Calif. Business: Cancer MabVax reverse-merged with Telik in a stock deal. Following the close, MabVax shareholders own 82% of the combined …

    Published on 9/1/2014
  • Merck, Pfizer deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer The pharmas partnered to conduct a Phase Ib trial to evaluate Mercks pembrolizumab with Pfizers crizotinib to…

    Published on 9/1/2014
  • Nerviano, Ignyta deal

    Nerviano Medical Sciences s.r.l., Nerviano, Italy Ignyta Inc. (NASDAQ:RXDX), San Diego, Calif. Business: Cancer Nerviano granted Ignyta exclusive, worldwide rights to develop and commercialize preclinical cancer …

    Published on 9/1/2014
  • NIH, KannaLife Sciences deal

    National Institutes of Health, Bethesda, Md. KannaLife Sciences Inc., Bayville, N.Y. Business: Neurology KannaLife said NIH granted the company a license to develop and commercialize U.S. Patent No. 6,630,507, which …

    Published on 9/1/2014
  • Nordion, Sterigenics deal

    Nordion Inc., Ottawa, Ontario Sterigenics International Inc., Deerfield, Ill. Business: Supply/Service, Other Sterigenics completed its acquisition of Nordion for $13 per share, or $826 million. In March, Sterigenics …

    Published on 9/1/2014
  • Novartis, TB Alliance deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Global Alliance for TB Drug Development, New York, N.Y. Business: Infectious Novartis granted the alliance exclusive, worldwide rights to the portfolio of preclinical …

    Published on 9/1/2014
  • Ono Pharmaceutical, Meiji Seika Pharma deal

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Meiji Seika Pharma Co. Ltd., Tokyo, Japan Business: Neurology Ono granted Meiji exclusive rights to develop and commercialize limaprost alfadex to treat lumbar …

    Published on 9/1/2014
  • Pfizer, Crohns & Colitis Foundation of America deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Crohns & Colitis Foundation of America, New York, N.Y. Business: Autoimmune The Crohns & Colitis Foundation of America (CCFA) partnered with Pfizer to discover small molecules to …

    Published on 9/1/2014
  • Prosarix, Evolva Holding deal

    Prosarix Ltd., Cambridge, U.K. Evolva Holding S.A. (SIX:EVE), Reinach, Switzerland Business: Computational chemistry/biology Evolva acquired in silico modeling company Prosarix in a stock deal worth up to CHF3.9 million…

    Published on 9/1/2014
  • ProteinSimple, Bio-Techne deal

    ProteinSimple, Santa Clara, Calif. Bio-Techne (NASDAQ:TECH), Minneapolis, Minn. Business: Proteomics Research supplier Bio-Techne completed its acquisition of ProteinSimple for about $300 million in cash (see BioCentury…

    Published on 9/1/2014
  • Questcor, Mallinckrodt deal

    Questcor Pharmaceuticals Inc., Anaheim, Calif. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Autoimmune, Inflammation Mallinckrodt completed its acquisition of Questcor in a cash and stock deal that values …

    Published on 9/1/2014
  • Rosetta Genomics deal

    Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel Business: Diagnostic Rosetta said it will provide its microRNA profiling and other services in a deal with an undisclosed pharmaceutical company to develop a miRNA-…

    Published on 9/1/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993